Compare NEON & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEON | CING |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1M | 26.8M |
| IPO Year | 2007 | 2021 |
| Metric | NEON | CING |
|---|---|---|
| Price | $1.90 | $4.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 212.9K | 189.9K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $2,197,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $43.34 | N/A |
| P/E Ratio | $3.64 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.72 | $3.20 |
| 52 Week High | $29.90 | $6.01 |
| Indicator | NEON | CING |
|---|---|---|
| Relative Strength Index (RSI) | 37.68 | 64.24 |
| Support Level | $1.85 | $4.41 |
| Resistance Level | $1.96 | $5.07 |
| Average True Range (ATR) | 0.09 | 0.36 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 48.48 | 68.32 |
Neonode Inc provides optical sensing solutions for contactless touch, and gesture sensing and also provides software solutions for machine perception that feature machine learning algorithms to detect and track persons and objects in video streams from cameras and other types of imagers. It markets and sells its solutions to customers in many different markets and segments including, office equipment, automotive, industrial automation, medical, military, and avionics. The company geographically operates in the United States, Japan, South Korea, Germany, Sweden, China, and other regions. A majority of its revenue is generated from Japan.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.